Elekta Gets FDA Nod for Monaco Treatment Planning for Proton Therapy, Strengthens IBA Partnership

By News Release

 

Monaco treatment planning for protons, a component of Elekta’s Treatment Management Solution, has received 510(k) clearance from the US FDA. Monaco brings robust functionality for proton therapy, featuring fast optimization and calculation via the Monte Carlo algorithm and user-configurable templates for different body sites to enable rapid proton plan creation. Elekta was among the first companies to support proton therapy with treatment planning and oncology information systems.

“Adding new technology to a department can be a complex task, and especially so for a highly advanced technique like proton therapy,” says Maurits Wolleswinkel, president Linac Solutions. “In partnership with IBA, however, Elekta’s Treatment Management solution, which includes Monaco, ProKnow and MOSAIQ Plaza digital tools – including MOSAIQ Oncology Information System – provides the ideal ecosystem to integrate proton therapy, helping centers expand their capabilities to choose the best care for their patients.”

The partnership with IBA, a provider of proton therapy solutions, pairs treatment hardware and supporting software for a proton therapy ecosystem. According to the companies, over 100,000 patients have been treated by IBA’s clinical partners.

“We are excited to continue expanding our successful partnership with Elekta. As proton therapy becomes an essential treatment modality for an increasing number of indications, it is critical to seamlessly integrate our solutions into the clinic and optimize workflows. Thanks to the joint in-house expertise of Elekta and IBA, and leveraging on the largest and most knowledgeable community of clinical partners in Proton Therapy, IBA is ideally positioned to complement Elekta’s integrated software solutions,” says Jeroen Cammeraat, chief commercial officer at IBA.

By harnessing Elekta’s oncology informatics infrastructure, users can benefit from department-wide integration and standardized workflows. All radiotherapy machines, including linear accelerators and proton systems, will be connected, thus optimizing efficiency. This infrastructure also gives clinicians powerful analytics tools to go beyond standard efficiency improvements, using the wealth of data that the department generates to pinpoint improvements within processes. Overall, this contributes to higher productivity and cost reduction, and enables value-based healthcare.

Elekta and IBA have been collaborating for the last 20 years to help oncology centers integrate the cancer treatment modality into their patient care environment.

Back To Top

Elekta Gets FDA Nod for Monaco Treatment Planning for Proton Therapy, Strengthens IBA Partnership.  Appl Rad Oncol. 

By News Release| March 05, 2021

About the Author

News Release

News Release


Copyright © Anderson Publishing, Ltd

 2021
    Agility CMS